Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Nuvation Bio Fiscal Q3 2021 Earnings Report - CapyFin

Nuvation Bio

NUVB · NYSE🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 -6.21%Q2 2025 -0.86%Q1 2025 +3.50%Q4 2024 +1.02%Q3 2024 +12.93%Q2 2024 -11.31%Q1 2024 -2.08%Q4 2023 +13.20%Q3 2023 +16.38%Q2 2023 +0.55%Q1 2023 +4.37%Q4 2022 +1.20%Q3 2022 -3.69%Q2 2022 +7.79%Q1 2022 -1.77%Q4 2021 -8.26%Q3 2021 +3.64%Q2 2021 +8.56%Q1 2021 +8.89%

Nov 10, 2021

•

Sep 30, 2021

Nuvation Bio Q3 2021 Earnings Report

Reported a net loss, progress in clinical trials, and pipeline expansion.

Key Takeaways

Nuvation Bio reported a net loss for Q3 2021, but highlighted progress in clinical trials for NUV-422 and NUV-868, as well as expansion of their pipeline with new drug candidates.

Reported a net loss of $53.1 million for the third quarter of 2021.

Advanced clinical trials for NUV-422 in HRD+ cancers and NUV-868 in lung cancer.

Expanded pipeline with the addition of new drug candidates targeting unmet medical needs.

Continued to strengthen the balance sheet to support ongoing research and development activities.

Total Revenue

EPS

-$0.11

Research and Development Expenses

$43.8M

Selling, General and Administrative Expenses

$9.3M

Cash and Equivalents